Literature DB >> 20425244

Biological properties of apolipoprotein a-I mimetic peptides.

Godfrey S Getz1, Geoffrey D Wool, Catherine A Reardon.   

Abstract

Apolipoprotein A-I (apoA-I) mimetic peptides resemble the physiochemical properties of the helices of apoA-I and show promise for the treatment of atherosclerotic vascular diseases and other chronic inflammatory disorders. These peptides have numerous properties, such as the ability to remodel high-density lipoprotein, sequester oxidized lipids, promote cholesterol efflux, and activate an anti-inflammatory process in macrophages, any or all of which may contribute to their antiatherogenic properties. In murine models, the 4F peptide attenuates early atherosclerosis but seems to require the addition of statins to influence more mature lesions. A recently developed method for the oral delivery of the peptides that protects them from proteolysis will facilitate further research on the mechanism of action of these peptides. This review focuses on the properties of the 4F peptide, although numerous apoA-I mimetics are under investigation and a single "best" peptide that mimics all of the properties of the antiatherogenic protein apoA-I has not been identified.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425244      PMCID: PMC3087815          DOI: 10.1007/s11883-010-0097-4

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  39 in total

Review 1.  Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action.

Authors:  Godfrey S Getz; Geoffrey D Wool; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2009-06       Impact factor: 4.776

2.  Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats.

Authors:  Zhenghao Zhang; Geeta Datta; Yun Zhang; Andrew P Miller; Paulina Mochon; Yiu-Fai Chen; John Chatham; G M Anantharamaiah; C Roger White
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-26       Impact factor: 4.733

3.  Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol.

Authors:  A J Mendez; G M Anantharamaiah; J P Segrest; J F Oram
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

4.  Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties.

Authors:  D W Garber; Y V Venkatachalapathi; K B Gupta; J Ibdah; M C Phillips; J B Hazelrig; J P Segrest; G M Anantharamaiah
Journal:  Arterioscler Thromb       Date:  1992-08

5.  The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor.

Authors:  Chongren Tang; Yuhua Liu; Peter S Kessler; Ashley M Vaughan; John F Oram
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

6.  Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Authors:  Brian J Van Lenten; Alan C Wagner; Chun-Ling Jung; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Andrew D Watson; Susan Hama; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-07-11       Impact factor: 5.922

7.  A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.

Authors:  Mohamad Navab; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Susan Hama; Greg Hough; Mayakonda N Palgunachari; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2009-02-18       Impact factor: 5.922

8.  Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function.

Authors:  W Sean Davidson; R A Gangani D Silva; Sandrine Chantepie; William R Lagor; M John Chapman; Anatol Kontush
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-26       Impact factor: 8.311

9.  An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.

Authors:  Geoffrey D Wool; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2009-05-11       Impact factor: 5.922

10.  Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice.

Authors:  Daniel Poeckel; Karin A Zemski Berry; Robert C Murphy; Colin D Funk
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

View more
  17 in total

1.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

2.  Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut?

Authors:  Geoffrey D Wool; Catherine A Reardon; Godfrey S Getz
Journal:  J Lipid Res       Date:  2014-08-01       Impact factor: 5.922

Review 3.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

4.  High density lipoprotein and cardiovascular diseases.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-07-26

5.  HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.

Authors:  Feng Su; Victor Grijalva; Kaveh Navab; Ekambaram Ganapathy; David Meriwether; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Mol Cancer Ther       Date:  2012-03-13       Impact factor: 6.261

Review 6.  Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDL.

Authors:  Baohai Shao
Journal:  Biochim Biophys Acta       Date:  2011-12-10

7.  Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity.

Authors:  Jennifer H Madenspacher; Kathleen M Azzam; Wanghua Gong; Kymberly M Gowdy; Michael P Vitek; Daniel T Laskowitz; Alan T Remaley; Ji Ming Wang; Michael B Fessler
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

8.  Apolipoprotein A-1 mimetic D-4F enhances isoflurane-induced eNOS signaling and cardioprotection during acute hyperglycemia.

Authors:  Ines Baotic; Zhi-Dong Ge; Filip Sedlic; Adrian Coon; Dorothee Weihrauch; David C Warltier; Judy R Kersten
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-10       Impact factor: 4.733

Review 9.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

10.  In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.

Authors:  Yannan Zhao; Audrey S Black; David J Bonnet; Bruce E Maryanoff; Linda K Curtiss; Luke J Leman; M Reza Ghadiri
Journal:  J Lipid Res       Date:  2014-06-29       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.